Humira Biosimilar Market 2025-2029: Unveiling Growth Developments with the Latest Updates

 Aimed at strategic decision-makers, this report explores current opportunities, emerging trends, and market dynamics shaping the humira biosimilar sector.

 

 Humira Biosimilar Market Analysis & Forecast: 2025–2029
 The humira biosimilar market size has grown rapidly in recent years. It will grow from $3.28 billion in 2024 to $3.67 billion in 2025 at a compound annual growth rate (CAGR) of 12.0%. The growth in the historic period can be attributed to growing demand for cost-effective alternatives, increasing approval of biosimilars by regulatory bodies, rising prevalence of autoimmune diseases, expanding healthcare access in emerging markets, and high cost of original biologics.
 
 The humira biosimilar market size is expected to see rapid growth in the next few years. It will grow to $5.82 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to advancements in biosimilar development technology, increasing healthcare cost containment efforts, expanding patent expirations of original biologics, enhancement in market access and reimbursement policies, and rising adoption of biosimilars in oncology and autoimmune diseases. Major trends in the forecast period include increasing approval of more biosimilars, advancements in manufacturing technologies, growing research and development activities, development and approval of biosimilar drugs, and advancement in drug formulation.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=24244&type=smp
 
 What Are The Factors Driving The Humira Biosimilar Market?
 The increasing prevalence of autoimmune diseases is expected to propel the growth of the humira biosimilar market going forward. Autoimmune diseases occur when the immune system mistakenly targets and attacks the body’s healthy cells, tissues, or organs. The growing prevalence of autoimmune diseases is linked to environmental pollution, which disrupts the immune system and heightens the risk of autoimmune reactions. Humira biosimilars work by blocking tumor necrosis factor (TNF), a protein that causes inflammation in autoimmune diseases. This helps reduce immune response, alleviating symptoms and preventing damage to healthy tissues. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government organization, in 2022, it was estimated that 514,000 people (2.0%) in Australia were living with rheumatoid arthritis, affecting 2.5% of females and 1.6% of males. Therefore, the increasing prevalence of autoimmune disorders is driving the growth of the humira biosimilar market.
 
 What Segments Are Covered In The Humira Biosimilar Market Report?
 The humira biosimilarmarket covered in this report is segmented — 
 
 1) By Product Type: Adalimumab Biosimilars; Other Types
 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
 3) By Application: Rheumatoid Arthritis; Psoriasis; Crohn’s Disease; Ulcerative Colitis; Ankylosing Spondylitis; Other Applications
 
 Subsegments:
 1) By Adalimumab Biosimilars: Fully Human Monoclonal Antibodies; Fragment Crystallizable (Fc) Region Modified Biosimilars; High-Concentration Formulations; Citrate-Free Formulations
 2) By Other Types: Biosimilars Of Other Tumor Necrosis Factor (TNF) Inhibitors; Interchangeable Biosimilars; Pegylated Biosimilars; Non-Adalimumab Monoclonal Antibody Biosimilars
 
 What Are The Future Trends Of The Humira Biosimilar Market?
 Major companies operating in the humira biosimilar market are focusing on developing advanced products, such as tumor necrosis factor (TNF) blockers, to offer more affordable options for autoimmune disease management. Tumor necrosis factor (TNF) blockers are biologic medications that suppress the action of TNF, a key protein that promotes inflammation. For instance, in July 2023, Organon & Co., a US-based pharmaceutical company, partnered with Samsung Bioepis Co., Ltd., a South Korea-based biotech company, to launch HADLIMA, a biosimilar to Humira. HADLIMA is available in both citrate-free high-concentration (100 mg/mL) and citrate-containing low-concentration (50 mg/mL) presentations, matching the options of the originator Humira, and aims to improve patient access and affordability. The product is offered at a significant discount, about 85% lower than Humira’s list price, and includes support programs for patients. This launch follows a global settlement allowing U.S. supply and marks a major milestone in expanding treatment options for chronic autoimmune diseases in the U.S.
 
 Which Are The Major Players Operating In The Global Humira Biosimilar Market?
 Major companies operating in the humira biosimilar market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., LG Chem Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Mylan N.V., Sandoz Group AG, Fresenius Kabi AG, Celltrion Inc., Biocon Limited, Torrent Pharmaceuticals, Samsung Bioepis Co. Ltd., Alvotech, Coherus BioSciences Inc., Zydus Cadila, Hetero Drugs Ltd., Fujifilm Kyowa Kirin Biologics, Synermore Biologics, CVS Health. 
 
 View the full humira biosimilar market report here:
 https://www.thebusinessresearchcompany.com/report/humira-biosimilar-global-market-report
 
 Humira Biosimilar Market Regional Insights:
 North America was the largest region in the humira biosimilar market in 2024. The regions covered in the humira biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company